Of the women exposed to natalizumab during pregnancy, 29 women gave birth to 28 healthy children; one child was born with hexadactyly (an extra finger), 5 pregnancies ended in an early miscarriage and one woman decided to undergo an elective termination of pregnancy. Importantly MS activity did not rebound during pregnancy or post partum after natalizumab was withdrawn. These data support the notion that an elective termination of pregnancy due to natalizumab exposure may not be necessary.
“Woman may find these data reassuring. However, I will still advise having a planned pregnancy.”